Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Terminated 3Unknown 1Suspended 1

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 5Other solid neoplasm 3Sarcoma 2Head & Neck 2Gynecologic 2Genitourinary 2NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Advanced NSCLC 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × famitinib × Thoracic × Clear all
NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
48 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
1 enrolled
Thoracic

Advanced NSCLC

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
450 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02356991 2019-11-04

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Suspended
137 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02766140 2019-01-18

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
12 enrolled
Thoracic

Non Squamous Non Small Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡